Search

Ardelyx Inc

Закрыт

СекторЗдравоохранение

3.76 0.8

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

3.7199999999999998

Макс.

3.91

Ключевые показатели

By Trading Economics

Доход

21M

-17M

Продажи

26M

121M

Прибыль на акцию

-0.07

Рентабельность продаж

-13.833

Сотрудники

489

EBITDA

20M

-10M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+264.44% upside

Дивиденды

By Acuity

Следующий отчет о доходах

29 окт. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-182M

1B

Предыдущая цена открытия

2.96

Предыдущая цена закрытия

3.76

Новостные настроения

By Acuity

67%

33%

307 / 340 Рейтинг в Healthcare

Ardelyx Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

21 авг. 2026 г., 19:16 UTC

Ardelyx Inc shares are higher today, continuing positive momentum since Thursday. No specific news was identified to explain the price movement.

20 авг. 2026 г., 20:01 UTC

News

Ardelyx Inc shares are lower amid a securities investigation into its revised IBSRELA revenue guidance, which was cut to $350-$370 million.

19 авг. 2026 г., 23:01 UTC

Ardelyx Inc. shares are higher in after-market trading, reflecting broader market gains. The stock remains below its 20-day moving average.

18 авг. 2026 г., 23:06 UTC

Ardelyx Inc. shares are roughly flat in after-market trading. The stock is down significantly compared to its month-ago close and below its 20-day moving average.

17 авг. 2026 г., 19:26 UTC

News

Ardelyx shares are lower as Levi & Korsinsky investigates potential federal securities law violations amid reduced revenue guidance for IBSRELA.

14 авг. 2026 г., 23:56 UTC

Ardelyx Inc. shares declined in after-market trading, continuing a broader trend of significant decline over the past month, remaining below the 20-day moving average.

13 авг. 2026 г., 23:01 UTC

Ardelyx Inc. shares advanced modestly in after-market trading, though they remain significantly below the 20-day moving average and near the one-month range's lower end.

12 авг. 2026 г., 23:26 UTC

Ardelyx Inc. shares were trading roughly flat in after-market hours. The stock has declined significantly over the past month amid broader market weakness.

11 авг. 2026 г., 19:56 UTC

Ardelyx Inc's shares are lower today, reflecting a broader decline in the biotechnology sector. Investors monitor macroeconomic factors ahead of the Consumer Price Index report.

10 авг. 2026 г., 23:56 UTC

Ardelyx Inc shares are higher in after-market trading, despite no specific news driving the move. Recent market conditions include cautious optimism following a jobs report.

7 авг. 2026 г., 23:31 UTC

News

Ardelyx shares are higher in after-market trading as TD Cowen maintains a Buy rating and lowers the price target to $10.

6 авг. 2026 г., 23:31 UTC

News
Social Media

Ardelyx Inc. reports Q2 revenue of $118.1 million, missing expectations. Shares decline in after-market trading following revised financial guidance and a net loss of $16.7 million.

3 авг. 2026 г., 19:16 UTC

Ardelyx Inc. shares are trading roughly flat with no specific news identified. The stock remains below its 20-day moving average.

31 июл. 2026 г., 19:16 UTC

Ardelyx Inc. shares are lower, reflecting broader market trends amid rising yields and inflationary pressures, particularly after a notable increase in crude oil prices.

30 июл. 2026 г., 23:51 UTC

Ardelyx Inc. shares are lower in after-market trading, remaining below their 20-day moving average amid broader market weakness.

22 июл. 2026 г., 19:31 UTC

Ardelyx Inc shares are higher in Wednesday's session, continuing a modest rise since Tuesday's close. The stock remains below its 20-day moving average.

20 июл. 2026 г., 19:02 UTC

Ardelyx shares are lower today, reflecting broader weakness in the biotechnology sector. The stock has declined since Friday's close with no specific news identified.

Сравнение c конкурентами

Изменение цены

Ardelyx Inc Прогноз

Целевая цена

By TipRanks

264.44% рост

Прогноз на 12 месяцев

Средняя 13.63 USD  264.44%

Максимум 18 USD

Минимум 9 USD

Основано на мнении 8 аналитиков Wall Street, спрогнозировавших целевые цены для Ardelyx Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

8 ratings

8

Покупка

0

Удержание

0

Продажа

Настроения

By Acuity

307 / 340Рейтинг в Здравоохранение

Новостные настроения

Свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Ardelyx Inc

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
help-icon Live chat